アバンディア4mg/8mg

※参考
アバンディアは、2型糖尿病の原因の一つであるインスリン抵抗性を直接改善し、内因性のインスリンの作用を高め、高血糖を是正する経口血糖降下剤です。
アバンディアは、1999年5月に米国にて優先審査で承認されて以来、現在までに欧米各国を含む世界101カ国で承認されいます。
日本においては、2型糖尿病(単独療法ならびにスルホニル尿素剤との併用)を効能として承認申請中の医薬品です。

The management of antidiabetic therapy should be individualized. Periodic fasting blood glucose measurements should be performed to monitor therapeytic response prior to up-titrating dose.
AVANDIA may be taken with or without food.

The usual starting dose of AVANDIA is 4 mg administered either as a single dose once daily or in divided doses twice daily. For patiants who respond inadequately following 12 weeks of treatment as determined by reduction in FPG, the dose may be increased to 8 mg administered as a single dose once daily or in divided doses twice daily. Reductions in glycaemic parameters by dose and regimen are described under Pharmacodynamics and Clinical Effects. In clinical trials, the 4 mg twice daily regimen resulted in the greatest reduction in FPG and HbA1c.